Generic Medicine Info
Indications and Dosage
Respiratory syncytial viral infections
Child: As 20 mg/mL soln: 300 mL (6 g) delivered via small particle aerosol generator over 12-18 hr daily for 3-7 days. Average aerosol concentration: 190 mcg/L of air.

Chronic hepatitis C
Adult: Rebetol (Schering-Plough) <65 kg: 400 mg both morning and evening; 65-80 kg: 400 mg in the morning and 600 mg in the evening; 81-105 kg: 600 mg both morning and evening; >105 kg: 600 mg in the morning and 800 mg in the evening. Use in combination w/ interferon alfa-2b or peginterferon alfa-2b. Copegus (Roche) Mono-infection (genotype 1 or 4): <75 kg: 400 mg in the morning and 600 mg in the evening; ≥75 kg: 600 mg both morning and evening. Mono-infection (genotype 2 or 3): 400 mg both morning and evening. Co-infection w/ HIV (regardless of genotype): 800 mg daily. Use in combination w/ interferon alfa-2a or peginterferon alfa-2a. Treatment duration: 48 wk (genotype 1 or 4 or HIV co-infection) or 24 wk (genotype 2 or 3).
Child: ≥3 yr Rebetol (Schering Plough) <47 kg: 15 mg/kg daily in 2 divided doses; 47-49 kg: 200 mg in the morning and 400 mg in the evening; 50-65 kg: 400 mg both morning and evening. Use in combination w/ interferon alfa-2b or peginterferon alfa-2b. Treatment duration: 48 wk (genotype 1) or 24 wk (genotype 2 or 3).
Special Patient Group
Patients who develop low Hb concentrations: Reduce dose.
Renal Impairment
CrCl (mL/min) Dosage
<50 Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Tab: Should be taken with food.
Cap: May be taken with or without food. Take consistently w/ respect to meals, either always w/ or always w/o meals.
Soln for inhalation: Dissolve 6 g in a at least 75 mL water for inj. Shake well, then transfer and dilute to a total vol of 300 mL of water for inj to prepare a 20 mg/mL soln.
Hypersensitivity. History of severe unstable cardiac disease, haemoglobinopathies, severe, debilitating medical conditions. CrCl <50 mL/min, severe hepatic impairment or decompensated liver cirrhosis. Male partners of pregnant women. Childn and adolescents w/ history of, or existing psychiatric disorders. Pregnancy and lactation.
Special Precautions
Patient w/ history of CHF, MI and/or previous or current arrhythmic disorders, ophthalmologic disorders, thyroid disorders, low CD4 count, substance use/abuse, COPD and asthma. Renal and hepatic impairment. Childn.
Adverse Reactions
Haemolytic anaemia, leucopenia, thrombocytopenia, aplastic anaemia, DM, autoimmune disorders, GI symptoms, pancreatitis, pulmonary embolism, bacterial pneumonia, pneumothorax, CV effects, chest pain, liver dysfunction, interstitial pneumonitis, lupus erythematosus, reticulocytosis, conjunctivitis, rash. Very rarely, Stevens-Johnson syndrome and toxic epidermal necrolysis; photosensitivity, growth retardation in childn; dental/periodontal disorders.
Potentially Fatal: MI, severe depression, suicidal ideation, relapse of drug abuse or overdose, bacterial infection.
Inhalation/Respiratory/PO: X
Patient Counseling Information
This drug may cause fatigue, somnolence or confusion, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor haematologic, cardiac, resp and ophth function; growth in paed patients; pregnancy tests mthly during and for 6 mth after discontinuation.
Drug Interactions
May exacerbate immunosuppression w/ azathioprine. Increased risk of mitochondrial toxicity and lactic acidosis in HIV-positive patients taking nucleoside reverse transcriptase inhibitor (e.g. didanosine, stavudine). Increased risk of anaemia w/ zidovudine. Decreased bioavailability w/ antacids containing Mg, Al and simethicone. Increased risk of lactic acidosis w/ other nucleoside analogues.
Description: Ribavirin is a synthetic nucleoside which has inhibitory action against respiratory syncytial virus, influenza virus and herpes simplex virus. The mechanism of action is not clear. It may act at several sites including cellular enzymes to interfere w/ viral nucleic acid synthesis. The mono- and triphosphate derivatives are known to be responsible for the antiviral action of the compound.
Absorption: Rapidly absorbed from the GI tract. Bioavailability: Approx 45-64%. Time to peak plasma concentration: W/in 1-2 hr.
Metabolism: Metabolised via reversible phosphorylation and degradation involving deribosylation and amide hydrolysis to form a triazole carboxyacid metabolite.
Excretion: Via urine as unchanged drug and metabolite. Terminal half-life: Approx 120-170 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Ribavirin, CID=37542, https://pubchem.ncbi.nlm.nih.gov/compound/Ribavirin (accessed on Jan. 22, 2020)

Cap/Tab: Store at 25°C. Oral soln: Store at 25°C or between 2-8°C. Inhalation: Store between 15-30°C.
MIMS Class
ATC Classification
J05AP01 - ribavirin ; Belongs to the class of antivirals for treatment of HCV infections. Used in the treatment of hepatitis C viral infections.
Anon. Ribavirin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 24/07/2015.

Buckingham R (ed). Ribavirin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/07/2015.

Copegus Tablet, Film Coated (Genentech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 20/07/2015.

Rebetol Capsule (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 20/07/2015.

Disclaimer: This information is independently developed by MIMS based on Ribavirin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Copegus
  • Rebetol
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in